drugset / Trial / NCT06756269
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
Timeline
- Start
- 2025-01-15
- Primary completion
- 2025-10-30
- Completion
- 2026-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) | Vaccine | — | Intramuscular |
| Comparator | 9-HPV vaccine | Vaccine | — | Intramuscular |